Latest News

Circassia Announces Grant of European Composition of Matter Patents for Three of Company's Lead Allergy T-Cell Vaccines

17 May 2010

Circassia Achieves Positive Phase II Clinical Results With Ragweed Allergy T-cell Vaccine

Results Mark Third Successful Phase II Study With ToleroMune T-Cell Vaccines

12 February 2010

Circassia Appoints Cathrin Petty to its Board of Directors

08 February 2010

Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-cell Vaccines Against House Dust Mite and Cat Allergies

19 January 2010

Circassia Raises £15million ($25million) in Oversubscribed Investment Round

11 December 2009

More recent news articles

Previous news articles

Did you know?

The average bed could be home to up to 1.5 million house dust mites